Exact Sciences (EXAS) EBITDA (2010 - 2025)

Exact Sciences (EXAS) has 16 years of EBITDA data on file, last reported at -$82.6 million in Q4 2025.

• EBITDA for Q4 2025 came in at -$82.6 million, up 90.58% year-over-year; the trailing twelve-month figure through Dec 2025 was -$206.3 million (up 80.33% YoY), and the FY2025 annual result was -$206.3 million, up 80.33% from the prior year.
• EBITDA retreated to -$82.6 million in Q4 2025 per EXAS's latest filing, from -$25.5 million in the prior quarter.
• Over five years, EBITDA peaked at $6.8 million in Q3 2023 and troughed at -$876.4 million in Q4 2024.
• A 5-year average of -$146.0 million and a median of -$101.4 million in 2024 frame the typical range for EBITDA.
• The sharpest annual moves came in 2023 and 2024: EBITDA jumped 104.96% in 2023, then slumped 1191.77% in 2024.
• A 5-year view of EBITDA shows it stood at -$221.4 million in 2021, then soared by 46.32% to -$118.9 million in 2022, then surged by 42.93% to -$67.8 million in 2023, then tumbled by 1191.77% to -$876.4 million in 2024, then surged by 90.58% to -$82.6 million in 2025.
• Business Quant data shows EXAS's EBITDA at -$82.6 million in Q4 2025, -$25.5 million in Q3 2025, and -$2.1 million in Q2 2025.